2,6 Further analysis to determine DLBCL pathogenesis and subtype includes an immunohistochemistry (IHC) panel, flow cytometry, and cytogenetics or fluorescence in situ hybridization (FISH). Flow ...

Laboratory of Natural and Targeted Small Molecule Drugs, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy ...

The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...

The study enrolled nine subjects with r/r DLBCL. Credit: Volha_R / Shutterstock. Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 ...

Real-world community oncology-based treatment patterns for first line axitinib plus pembrolizumab in advanced renal cell carcinoma: Initial dosing, dose reductions and clinical outcomes. Efficacy and ...

The Uganda workers were aware from the earliest recognition of this tumor that the histology was not unique to Africa and that tumors with identical histology and similar presentations occurred ...

DLBCL is a cancer of the lymphatic system and the most common and difficult to treat form of large B-cell lymphoma, which is a type of non-Hodgkin lymphoma. Nearly 40% of patients experience relapse ...

Diffuse large B cell lymphoma (DLBCL) is a genetically highly heterogeneous disease. Yet, to date, the vast majority of patients receive standardized frontline chemo-immune-therapy consisting of an ...

Histology from a punch biopsy as well as on tissue obtained during neurosurgical intervention led to the diagnosis of DLBCL and CAR T cell therapy was performed in November 2020. Together, these ...